The company has received approval for its pulse biopsy system NeoNavia from the US Food and Drug Administration, FDA.
“The FDA approval for NeoNavia is a major milestone for NeoDynamics and a stamp of quality for both the product and NeoDynamics as a whole,” says Anna Eriksrud, CEO of NeoDyna